Search | Clinical Trials Finder

Conditions: Chronic Hepatitis C Infection
Interventions: ABT-267, ABT-450, ABT-333, Ritonavir, Ribavirin; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Bakersfield, California • Orlando, Florida • Annapolis, Maryland + 1 more

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Conditions: Hepatitis C, HIV Infections
Interventions: Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL/VOX, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hepatitis C Virus Infection
Interventions: SOF/VEL, SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 50
States / cities: Long Beach, California • Los Angeles, California • Palo Alto, California + 35 more

Conditions: Hepatitis C Virus
Interventions: ribavirin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Peg-IFN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 67
States / cities: Birmingham, Alabama • Bakersfield, California • Colton, California + 53 more

Conditions: HIV-1 Infection, Hepatitis
Interventions: Sofosbuvir, Ribavirin, Ledipasvir/Sofosbuvir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 12
States / cities: San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Chronic Hepatitis C
Interventions: Peginterferon alfa-2a with Ribavirin, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, HIV Infections
Interventions: telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose); Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Beverly Hills, California • San Diego, California • San Francisco, California + 8 more

Conditions: Chronic Hepatitis C
Interventions: GS-5885, GS-9451, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 26
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 20 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 53
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 50 more

Conditions: Hepatitis C Virus
Interventions: BMS-790052, Placebo, peginterferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Chronic Hepatitis C Virus
Interventions: LDV/SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic HCV Infection
Interventions: LDV/SOF, RBV, GS-9669; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Hepatitis C
Interventions: SOF, RBV, Placebo to match SOF, Placebo to match RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 51
States / cities: Coronado, California • Los Angeles, California • San Diego, California + 41 more

Conditions: Hepatitis C, Human Immunodeficiency Virus
Interventions: SOF, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 23 more

Conditions: Hepatitis C
Interventions: SOF, VEL, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Long Beach, California • Los Angeles, California • Pasadena, California + 37 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 14
States / cities: Chicago, Illinois • Indianapolis, Indiana • New Orleans, Louisiana + 11 more

Conditions: Hepatitis C
Interventions: SOF, RBV, Peg-IFN; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Riverside, California • San Diego, California • San Francisco, California + 19 more

Conditions: Hepatitis C, Chronic
Interventions: Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 42
States / cities: Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more

Conditions: Chronic Hepatitis C
Interventions: Sofosbuvir, RBV, PEG; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 55
States / cities: Birmingham, Alabama • Coronado, California • Los Angeles, California + 43 more

Conditions: Hepatitis C, HCV
Interventions: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 31
States / cities: Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more

Search by objective public record fields.

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects